Medifast (MED) Stock Price

Medifast Price

🇺🇸NYSE·CLOSED
12.10USD
Market closed
Today +/-
Today %

Medifast (MED) Stock | ISIN US58470H1014 | WKN 889384. The current Medifast stock price is 12.1 USD (2026). Revenue is 355.62 M USD. Net income is -1.44 M USD. The P/E ratio is -92.16. Market capitalization is 132.65 M USD. Medifast operates in the Non-cyclical consumption sector.

Medifast stock price

Ex-Dividend
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Medifast over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Medifast stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Medifast's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Medifast Stock Price History
DateMedifast Price
Access this data via the Eulerpool API

Medifast Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2005
40.1 M USD
3.5 M USD
2.1 M USD
Jan 1, 2006
74.1 M USD
7.4 M USD
5.2 M USD
Jan 1, 2007
83.8 M USD
5.7 M USD
3.4 M USD
Jan 1, 2008
110.1 M USD
7.4 M USD
4.3 M USD
Jan 1, 2009
169.7 M USD
18.5 M USD
11.4 M USD
Jan 1, 2010
257.6 M USD
31.6 M USD
19.6 M USD
Jan 1, 2011
298.2 M USD
27.4 M USD
18.5 M USD
Jan 1, 2012
318.6 M USD
27.1 M USD
15.9 M USD
Jan 1, 2013
324.1 M USD
38.4 M USD
24 M USD
Jan 1, 2014
285.3 M USD
30.2 M USD
13.2 M USD
Jan 1, 2015
272.8 M USD
28.7 M USD
20.1 M USD
Jan 1, 2016
274.5 M USD
26.9 M USD
17.8 M USD
Jan 1, 2017
301.6 M USD
39.6 M USD
27.7 M USD
Jan 1, 2018
501 M USD
69.1 M USD
55.8 M USD
Jan 1, 2019
713.7 M USD
91 M USD
77.9 M USD

Medifast Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 10, 2026, 12:36 PM
 
REVENUE (M USD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M USD)
NET INCOME (M USD)
NET INCOME GROWTH (%)
DIV. (USD)
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Medifast generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Medifast retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Medifast's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Medifast has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Medifast's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Medifast stock margins

The Medifast margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Medifast. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Medifast.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2005
74.81 %
8.73 %
5.24 %
Jan 1, 2006
75.3 %
9.99 %
7.02 %
Jan 1, 2007
74.34 %
6.8 %
4.06 %
Jan 1, 2008
71.84 %
6.72 %
3.91 %
Jan 1, 2009
73.31 %
10.9 %
6.72 %
Jan 1, 2010
74.73 %
12.27 %
7.61 %
Jan 1, 2011
75.29 %
9.19 %
6.2 %
Jan 1, 2012
74.04 %
8.51 %
4.99 %
Jan 1, 2013
74.24 %
11.85 %
7.41 %
Jan 1, 2014
73.33 %
10.59 %
4.63 %
Jan 1, 2015
73.79 %
10.52 %
7.37 %
Jan 1, 2016
74.94 %
9.8 %
6.48 %
Jan 1, 2017
75.53 %
13.13 %
9.18 %
Jan 1, 2018
75.83 %
13.79 %
11.14 %
Jan 1, 2019
75.23 %
12.75 %
10.91 %

Medifast Stock Revenue, EBIT, Earnings per Share

The Medifast earnings per share therefore indicates how much revenue Medifast has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2005
3.13 USD
0.27 USD
0.16 USD
Jan 1, 2006
5.49 USD
0.55 USD
0.39 USD
Jan 1, 2007
6.16 USD
0.42 USD
0.25 USD
Jan 1, 2008
7.7 USD
0.52 USD
0.3 USD
Jan 1, 2009
11.54 USD
1.26 USD
0.78 USD
Jan 1, 2010
17.64 USD
2.16 USD
1.34 USD
Jan 1, 2011
21 USD
1.93 USD
1.3 USD
Jan 1, 2012
23.26 USD
1.98 USD
1.16 USD
Jan 1, 2013
23.49 USD
2.78 USD
1.74 USD
Jan 1, 2014
22.29 USD
2.36 USD
1.03 USD
Jan 1, 2015
22.55 USD
2.37 USD
1.66 USD
Jan 1, 2016
23.07 USD
2.26 USD
1.5 USD
Jan 1, 2017
24.93 USD
3.27 USD
2.29 USD
Jan 1, 2018
41.4 USD
5.71 USD
4.61 USD
Jan 1, 2019
58.98 USD
7.52 USD
6.44 USD

Medifast business model & stock analysis

Medifast Inc. is a leading provider of health and wellness solutions, with its headquarters in Baltimore, Maryland. The company was founded in 1980 by Dr. William Vitale and has since experienced continuous growth. Medifast's nutrition and health products are available in the United States, Canada, and Puerto Rico.

Medifast SWOT Analysis

Strengths

Medifast Inc has several strengths that contribute to its success in the market.

  • Strong brand recognition and reputation.
  • Well-established distribution network.
  • Diverse range of products and services.
  • Proven track record of customer satisfaction.
  • Effective marketing strategies.

Weaknesses

Despite its strengths, Medifast Inc also faces certain weaknesses that need to be addressed.

  • Dependency on a limited number of suppliers.
  • Relatively high pricing compared to competitors.
  • Inadequate international presence.
  • Limited product diversification within certain segments.

Opportunities

Medifast Inc has several opportunities in the market that can drive its future growth.

  • Increasing consumer awareness and demand for health-focused products.
  • Growing population of individuals seeking weight management solutions.
  • Potential partnerships with complementary businesses.
  • Expansion into untapped international markets.
  • Technological advancements enabling efficient product development and delivery.

Threats

Medifast Inc must be aware of potential threats that could impact its business negatively.

  • Intense competition from both traditional and emerging players.
  • Government regulations and policies affecting the health and wellness industry.
  • Economic downturns leading to decreased consumer spending.
  • Shifts in consumer preferences towards alternative weight management methods.
  • Negative publicity or product quality issues affecting brand perception.

Medifast Segments

Medifast Eulerpool Fair Value

Medifast historical P/E ratio, EBIT multiple, and P/S ratio

Medifast annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Medifast shares outstanding

The number of shares was Medifast in 2025 — This indicates how many shares 10.963 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2005
12.8 M base_Shares
Jan 1, 2006
13.5 M base_Shares
Jan 1, 2007
13.6 M base_Shares
Jan 1, 2008
14.3 M base_Shares
Jan 1, 2009
14.7 M base_Shares
Jan 1, 2010
14.6 M base_Shares
Jan 1, 2011
14.2 M base_Shares
Jan 1, 2012
13.7 M base_Shares
Jan 1, 2013
13.8 M base_Shares
Jan 1, 2014
12.8 M base_Shares
Jan 1, 2015
12.1 M base_Shares
Jan 1, 2016
11.9 M base_Shares
Jan 1, 2017
12.1 M base_Shares
Jan 1, 2018
12.1 M base_Shares
Jan 1, 2019
12.1 M base_Shares

Medifast Dividend History

9 years of dividend payments

YearAnnual DividendYoY ChangePayments
20234.95USD 24.5%
20226.56USD 15.5%
20215.68USD 25.7%
20204.52USD 33.7%
20193.38USD 54.3%
20182.19USD 52.1%
20171.44USD 34.6%
20161.07USD 328.0%
20150.25USD

Medifast dividend history and estimates

In 2025, Medifast paid a dividend amounting to 0.49 USD. Dividend means that Medifast distributes a portion of its profits to its owners.
  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Invalid Date
0.25 USD
0.75 USD
Jan 1, 2016
1.07 USD
0 USD
Jan 1, 2017
1.44 USD
0 USD
Jan 1, 2018
2.19 USD
0 USD
Jan 1, 2019
3.38 USD
0 USD
Jan 1, 2020
4.52 USD
0 USD
Jan 1, 2021
5.68 USD
0 USD
Jan 1, 2022
6.56 USD
0 USD
Invalid Date
4.95 USD
1.65 USD
Invalid Date
0 USD
0.49 USD

Medifast dividend payout ratio

In 2025, Medifast had a payout ratio of 48.96%. The payout ratio indicates the percentage of the company's profits that Medifast distributes as dividends.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2005
48.29 %
Jan 1, 2006
48.29 %
Jan 1, 2007
48.29 %
Jan 1, 2008
48.29 %
Jan 1, 2009
48.29 %
Jan 1, 2010
48.29 %
Jan 1, 2011
48.29 %
Jan 1, 2012
48.29 %
Jan 1, 2013
48.29 %
Jan 1, 2014
48.29 %
Jan 1, 2015
15.06 %
Jan 1, 2016
71.81 %
Jan 1, 2017
63.16 %
Jan 1, 2018
47.4 %
Jan 1, 2019
52.57 %
Price targets and forecasts for Medifast are not yet available.

Medifast Earnings Estimates

Medifast Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
5/4/2026-0.53USD69.89 MUSD2026 Q1
2/24/2026-0.83USD74.54 MUSD2025 Q4
2/17/2026-0.83USD74.54 MUSD2025 Q4
4/29/20241.96USD219.27 MUSD2024 Q1
2/19/20240.91USD185.99 MUSD2023 Q4
8/1/20233.88USD410.87 MUSD2023 Q2
5/1/20233.29USD379.91 MUSD2023 Q1
2/21/20232.24USD335.05 MUSD2022 Q4
11/3/20221.93USD354.54 MUSD2022 Q3
8/3/20223.27USD454.57 MUSD2022 Q2
...

EESG©

Eulerpool ESG Scorecard© for the Medifast stock

30/100
8
Environment
38
Social
44
Governance
E

Environment

20
Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees49
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Medifast shareholder structure

% Name
7.41868%
Renaissance Technologies LLC
Renaissance Technologies LLC
7.29061%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
7.25574%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
3.84173%
Charles Schwab Investment Management, Inc.
Charles Schwab Investment Management, Inc.
3.82213%
Two Sigma Investments, LP
Two Sigma Investments, LP
3.7499%
Acadian Asset Management LLC
Acadian Asset Management LLC
3.61552%
BofA Global Research (US)
BofA Global Research (US)
2.95242%
Parametric Portfolio Associates LLC
Parametric Portfolio Associates LLC
2.93012%
D. E. Shaw & Co., L.P.
D. E. Shaw & Co., L.P.
2.31326%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
...

Medifast Executives and Management Board

DC

Mr. Daniel Chard

(60)

Chairman of the Board, Chief Executive Officer · since 2016

Compensation5.61 M USD
JM

Mr. James Maloney

(57)

Chief Financial Officer

Compensation1.35 M USD
NJ

Mr. Nicholas Johnson

(45)

Chief Field Operations Officer

Compensation1.13 M USD
JG

Mr. Jason Groves

(54)

Chief Legal Officer, Corporate Secretary · since 2009

Compensation1.09 M USD
AT

Mr. Anthony Tyree

(60)

Chief Marketing Officer, Chief Business Operations

Compensation1.07 M USD

Frequently asked questions about Medifast

Medifast Inc. operates under a direct selling business model, providing weight management and health products. This company offers various weight loss programs, including their popular Optavia brand. Medifast sells its products through a network of independent distributors and coaches, who assist individuals in achieving their health and wellness goals. By emphasizing the importance of nutrition, portion control, and regular exercise, Medifast aims to help customers maintain a healthier lifestyle. With its extensive product line and dedicated network of distributors, Medifast Inc. remains committed to assisting individuals in achieving sustainable weight loss and overall well-being.

All fundamentals and in-depth analysis of Medifast

Our stock analysis for Medifast Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medifast Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.